stonks4u
Sign up free
IMMX logo

IMMX Immix Biopharma, Inc.

NASDAQ Capital Market · Biotechnology · Healthcare

$10.97
+0.05 (+0.46%)

Immix Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to creating a range of tissue-specific therapies. Operating in both the United States and Australia, their primary focus areas are oncology (cancer) and inflammatory diseases. Their product pipeline includes IMX-110, which is currently undergoing Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and various s…

Market Cap: $596.79Mwww.immixbio.com

Price (90d)

No price history yet — the daily price refresh runs once a day.

Signal Score (90d)

100
100
Aug 11Aug 11

Quote

Day Range
$10.35 – $11.07
52-Week Range
$1.94 – $12.14
Volume
$1.29M
Market Cap
$596.79M
50-Day Avg
$9.58
200-Day Avg
$7.76
Prev Close
$10.92
Open
$10.76

Valuation & Ratios

P/E Ratio
-5.88
EPS
$-0.89
P/B Ratio
1.84
P/S Ratio
0.00
Debt/Equity
0.01
Current Ratio
10.01
Dividend Yield
+0.0%
Gross Margin
+0.0%

Returns & Efficiency

Return on Equity
-31.4%
Return on Assets
-28.1%
FCF Yield
-14.3%
EV/EBITDA
-2.69

Revenue & Net Income (Annual)

Fiscal YearRevenueNet IncomeEPS
2025$0.00$-29.44M$-0.89
2024$0.00$-21.61M$-0.76
2023$0.00$-15.43M$-0.89
2022$0.00$-8.23M$-0.59
2021$0.00$-24.38M$-6.64

Social Signal Score

50
5d
50
1 mentions
—
30d
50
1 mentions
—
60d
50
1 mentions
—
90d
50
1 mentions
—
news: 1

Earnings

Fri, Nov 6(in 3 months)

Consensus estimate $-0.17 per share

3of 7 quarters beat consensus

Typical surprise -4.8% (median, so one quarter with a near-zero estimate can't distort it)

  • Fri, Aug 7$-0.18 vs $-0.17miss
  • Thu, May 7$-0.18 vs $-0.21beat
  • Wed, Mar 25$-0.27 vs $-0.21miss
  • Fri, Nov 7$-0.24 vs $-0.19miss
  • Fri, Aug 8$-0.22 vs $-0.21miss
  • Thu, May 8$-0.15 vs $-0.23beat

Estimates and results for IMMX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.

Valuation

IMMXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.

Mentions (1)

  • Newsglobenewswire.com·3d ago·Neutral

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMX NEW YORK, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Immix Biopharma, Inc. (“Immix” or the “Company”) (NASDAQ: IMMX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

    View source ↗